Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS) : A Randomized, Double-Blind Trial. / Muskiet, Marcel H. A.; Tonneijck, Lennart; Smits, Mark M.; Kramer, Mark H. H.; Ouwens, D. Margriet; Hartmann, Bolette; Holst, Jens J.; Touw, Daan J.; Danser, A. H. Jan; Joles, Jaap A.; van Raalte, Daniel H.

In: Diabetes Care, Vol. 43, No. 11, 2020, p. 2889-2893.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Muskiet, MHA, Tonneijck, L, Smits, MM, Kramer, MHH, Ouwens, DM, Hartmann, B, Holst, JJ, Touw, DJ, Danser, AHJ, Joles, JA & van Raalte, DH 2020, 'Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial', Diabetes Care, vol. 43, no. 11, pp. 2889-2893. https://doi.org/10.2337/dc20-0902

APA

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Ouwens, D. M., Hartmann, B., Holst, J. J., Touw, D. J., Danser, A. H. J., Joles, J. A., & van Raalte, D. H. (2020). Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care, 43(11), 2889-2893. https://doi.org/10.2337/dc20-0902

Vancouver

Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Ouwens DM, Hartmann B et al. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care. 2020;43(11):2889-2893. https://doi.org/10.2337/dc20-0902

Author

Muskiet, Marcel H. A. ; Tonneijck, Lennart ; Smits, Mark M. ; Kramer, Mark H. H. ; Ouwens, D. Margriet ; Hartmann, Bolette ; Holst, Jens J. ; Touw, Daan J. ; Danser, A. H. Jan ; Joles, Jaap A. ; van Raalte, Daniel H. / Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS) : A Randomized, Double-Blind Trial. In: Diabetes Care. 2020 ; Vol. 43, No. 11. pp. 2889-2893.

Bibtex

@article{9576545b1460460fb467065cb186e2d5,
title = "Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial",
abstract = "OBJECTIVE To compare effects of the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin with those of a sulfonylurea on renal physiology in metformin-treated patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. Fasting glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearances. Fractional excretions, urinary damage markers, and circulating DPP-4 substrates (among others, glucagon-like peptide 1 and stromal cell-derived factor-1 alpha [SDF-1 alpha]) were measured. RESULTS HbA(1c)reductions were similar with linagliptin (-0.45 +/- 0.09%) and glimepiride (-0.65 +/- 0.10%) after 8 weeks (P= 0.101). Linagliptin versus glimepiride did not affect GFR, ERPF, estimated intrarenal hemodynamics, or damage markers. Only linagliptin increased fractional excretion (FE) of sodium (FENa) and potassium, without affecting FE of lithium. Linagliptin-induced change in FE(Na)correlated with SDF-1 alpha (R= 0.660) but not with other DPP-4 substrates. CONCLUSIONS Linagliptin does not affect fasting renal hemodynamics compared with glimepiride in T2DM patients. DPP-4 inhibition promotes modest natriuresis, possibly mediated by SDF-1 alpha, likely distal to the macula densa.",
keywords = "GLP-1 RECEPTOR, NATRIURESIS, KIDNEY",
author = "Muskiet, {Marcel H. A.} and Lennart Tonneijck and Smits, {Mark M.} and Kramer, {Mark H. H.} and Ouwens, {D. Margriet} and Bolette Hartmann and Holst, {Jens J.} and Touw, {Daan J.} and Danser, {A. H. Jan} and Joles, {Jaap A.} and {van Raalte}, {Daniel H.}",
year = "2020",
doi = "10.2337/dc20-0902",
language = "English",
volume = "43",
pages = "2889--2893",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "11",

}

RIS

TY - JOUR

T1 - Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS)

T2 - A Randomized, Double-Blind Trial

AU - Muskiet, Marcel H. A.

AU - Tonneijck, Lennart

AU - Smits, Mark M.

AU - Kramer, Mark H. H.

AU - Ouwens, D. Margriet

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Touw, Daan J.

AU - Danser, A. H. Jan

AU - Joles, Jaap A.

AU - van Raalte, Daniel H.

PY - 2020

Y1 - 2020

N2 - OBJECTIVE To compare effects of the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin with those of a sulfonylurea on renal physiology in metformin-treated patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. Fasting glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearances. Fractional excretions, urinary damage markers, and circulating DPP-4 substrates (among others, glucagon-like peptide 1 and stromal cell-derived factor-1 alpha [SDF-1 alpha]) were measured. RESULTS HbA(1c)reductions were similar with linagliptin (-0.45 +/- 0.09%) and glimepiride (-0.65 +/- 0.10%) after 8 weeks (P= 0.101). Linagliptin versus glimepiride did not affect GFR, ERPF, estimated intrarenal hemodynamics, or damage markers. Only linagliptin increased fractional excretion (FE) of sodium (FENa) and potassium, without affecting FE of lithium. Linagliptin-induced change in FE(Na)correlated with SDF-1 alpha (R= 0.660) but not with other DPP-4 substrates. CONCLUSIONS Linagliptin does not affect fasting renal hemodynamics compared with glimepiride in T2DM patients. DPP-4 inhibition promotes modest natriuresis, possibly mediated by SDF-1 alpha, likely distal to the macula densa.

AB - OBJECTIVE To compare effects of the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin with those of a sulfonylurea on renal physiology in metformin-treated patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. Fasting glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearances. Fractional excretions, urinary damage markers, and circulating DPP-4 substrates (among others, glucagon-like peptide 1 and stromal cell-derived factor-1 alpha [SDF-1 alpha]) were measured. RESULTS HbA(1c)reductions were similar with linagliptin (-0.45 +/- 0.09%) and glimepiride (-0.65 +/- 0.10%) after 8 weeks (P= 0.101). Linagliptin versus glimepiride did not affect GFR, ERPF, estimated intrarenal hemodynamics, or damage markers. Only linagliptin increased fractional excretion (FE) of sodium (FENa) and potassium, without affecting FE of lithium. Linagliptin-induced change in FE(Na)correlated with SDF-1 alpha (R= 0.660) but not with other DPP-4 substrates. CONCLUSIONS Linagliptin does not affect fasting renal hemodynamics compared with glimepiride in T2DM patients. DPP-4 inhibition promotes modest natriuresis, possibly mediated by SDF-1 alpha, likely distal to the macula densa.

KW - GLP-1 RECEPTOR

KW - NATRIURESIS

KW - KIDNEY

U2 - 10.2337/dc20-0902

DO - 10.2337/dc20-0902

M3 - Journal article

C2 - 32900785

VL - 43

SP - 2889

EP - 2893

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 11

ER -

ID: 251640226